Day One Biopharmaceuticals Inc
Day One Biopharmaceuticals — Investor Presentation (March 2022)
28 slides from Day One Biopharmaceuticals's investor presentation, Mar 7, 2022
Slide 1: Targeted Therapies for People of All Ages
Targeted Therapies for People of All Ages March 2022
Slide 2: Disclaimer
Disclaimer This presentation and the accompanying oral commentary contain forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements are inherently subject to risks and uncertainties, some
Slide 3: Day One: Cancer Drug Development for People of All Ages
Day One: Cancer Drug Development for People of All Ages Mission That Creates Value Specialized Team DAY101 (tovorafenib) Lead Program Growing Portfolio and Runway Beyond Clinical Milestones Develop medicines for genomically-defined cancers Goal is to establish first-in-class position through rapid p
Slide 4: Pediatric Markets Create Opportunity for High Impact and Capital Efficiency
Pediatric Markets Create Opportunity for High Impact and Capital Efficiency Lack of approved products create potential first-in-class opportunities Pricing flexibility for important new therapies Supportive and engaged advocacy and investigator community desiring better treatment options Early engag
Slide 5: A Senior Team with Deep Experience in Pediatric and Adult Oncology
A Senior Team with Deep Experience Developing and Commercializing Products in Pediatric and Adult Oncology Markets Mike Preigh, PhD Chief Technical Officer Head of CMC at Array for 10+ years. Brought >20 drug candidates to IND & clinical development Lisa Bowers Chief Commercial Officer CEO of Rhia V
Slide 6: Our Pipeline
Our Pipeline Product Candidate Indication Preclinical Phase 1 Phase 2 Phase 3 Milestones DAY101 (tovorafenib) Type II Pan-RAF Inhibitor Relapsed pLGG Frontline pLGG RAF-altered solid tumors2 (monotherapy) Pimasertib MEK 1/2 Inhibitor MAPK-altered solid tumors3 (Combo w/DAY101) FDA Breakthrough Thera
Slide 7: DAY101 (tovorafenib) Type II Pan-RAF Inhibitor
DAY101 (tovorafenib) Type II Pan-RAF Inhibitor
Slide 8: DAY101 Monotherapy Approach Focused on RAF Fusions; Combination Addresses Broad MAPK Alterations
DAY101 (tovorafenib): Monotherapy Approach is Focused on RAF Fusions While Our Combination Strategy Addresses a Broad Set of MAPK Alterations DAY101 (tovorafenib) is a type II RAF inhibitor that selectively inhibits both monomeric and dimeric RAF kinase DAY101’s inhibition of both RAF monomers and d
Slide 9: The Current pLGG Treatment Paradigm Reflects the Unrelenting Nature of this Chronic Brain Tumor
The Current pLGG Treatment Paradigm Reflects the Unrelenting Nature of this Chronic Brain Tumor Because many pLGGs undergo senescence when patients reach their 20s, the goal of therapy is to maximize tumor control while minimizing treatment-associated toxicities from surgery, chemotherapy, and radia
Slide 10: PNOC014 Study Results Demonstrated Responses or Stable Disease in Majority of pLGG Patients
PNOC014 Study Results Demonstrated Responses or Stable Disease in Majority of pLGG Patients Treated with DAY101 (tovorafenib) Of the eight patients with RAF fusions (7 BRAF, 1 CRAF), two patients achieved a complete response by Response Assessment for Neuro-Oncology (RANO), three had a partial respo
Slide 11: Results from Independent Radiology Review of PNOC014
Results from Independent Radiology Review of PNOC014 RAPNO: Response assessment for pediatric neuro-oncology (exploratory) RANO: Response assessment for neuro-oncology (FDA standard) Volumetric image analysis (exploratory) Best response from baseline Date of data cutoff: 02 JAN 2020 Wright K et. al.
Slide 12: Multiple Rapid, Deep and Durable Responses Observed in PNOC014
Multiple Rapid, Deep and Durable Responses Observed following Initiation of DAY101 (tovorafenib) Treatment of pLGG Patients in PNOC014 Date of data cutoff: 02 JAN 2020 Adapted from Wright K et. al. Neuro Oncology Abstract CTNI-19. 2020 Fangusaro J et al. Lancet Oncol 2019
Slide 13: Drug-related Adverse Events Showed Favorable Safety and Tolerability Profile in pLGG
Drug-related Adverse Events Observed for DAY101 (tovorafenib) in PNOC014 Showed Favorable Safety and Tolerability Profile in pLGG Toxicities Grade 1-2 Grade 3 Grade 4 Anemia 6 (67%) Hypophosphatemia 4 (44%) Fatigue 5 (55%) Rash 8 (89%) Achromotrichia 7 (78%) Pruritis 6 (67%) Photosensitivity 1 (11%)
Slide 14: Pivotal Phase 2 Study of Monotherapy DAY101 in pLGG (FIREFLY-1)
Pivotal Phase 2 Study of Monotherapy DAY101 (tovorafenib) in pLGG (FIREFLY-1) Abbreviations: LGG, low-grade glioma; ORR, objective response rate; C, cycle; D, day Study Design Screening Day –28 to 0 Enrollment/Baseline (C1D1) MRI: Baseline and every 3rd cycle Study Drug Administration 420mg/m2 QW El
Slide 15: Incidence and Prevalence of BRAF-altered pLGG in the U.S.
Incidence and Prevalence of BRAF-altered pLGG in the U.S. 2020 Estimated Incidence Under 25 US Population1 ~105,000,000 Rate of CNS Tumors (0.00521%)2 ~5,500 Gliomas (63%)2 ~3,500 Low Grade (77%)2 ~2,600 Has Received Drug Tx (58%)2 ~1,500 BRAF Mutated (70%)2 ~1,100 2017 Estimated SEER Prevalence Und
Slide 16: Our Pipeline
Our Pipeline Product Candidate Indication Preclinical Phase 1 Phase 2 Phase 3 Anticipated Milestones DAY101 (tovorafenib) Type II Pan-RAF Inhibitor Relapsed pLGG Frontline pLGG RAF-altered solid tumors2 (monotherapy) Pimasertib MEK 1/2 Inhibitor MAPK-altered solid tumors3 (Combo w/DAY101) FDA Breakt
Slide 17: DAY101 is Active as a Monotherapy in Patients with RAF-altered Adult Solid Tumors
DAY101 (tovorafenib) is Active as a Monotherapy in Patients with RAF-altered Adult Solid Tumors and Has Shown Strong Synergy Preclinically in Combination Clinical activity demonstrated in relapsed melanoma patients; preclinical activity demonstrated in RAF fusions, BRAF non-V600 mutations, and BRAF
Slide 18: Next-generation RAF Inhibitors are Unique in Their Ability to Address Adult Cancers
Next-generation RAF Inhibitors are Unique in Their Ability to Address Adult Cancers Associated with RAF Wild-type Fusions Botton T et al, Cell Reports, 2019 LY3009120: Lilly pan-RAFi Lifirafenib: Beigene pan-RAF/EGFRi CCT196969: CRUK RAF ”paradox breaker” Springworks 2020 Corp Presentation BRAFwt fu
Slide 19: Phase 1b/2a Study of Monotherapy DAY101 in Solid Tumors (FIRELIGHT-1)
Phase 2 Study of Monotherapy DAY101 (tovorafenib) in Solid Tumors (FIRELIGHT-1) Trial Design1 Single arm, open-label, global phase 1b/2a study n = 40 patients (approximately) Eligibility: patients aged 12 years and older with non-hematologic tumor with an activating BRAF fusion, CRAF/RAF1 fusion, or
Slide 20: Strong Scientific Rationale for Combining DAY101 with Additional MAPK Pathway Inhibitors
Strong Scientific Rationale for Combining DAY101 (tovorafenib) with Additional MAPK Pathway Inhibitors Potential combinations Type II RAFi + MEKi Rationale BRAF fusion dimers are effectively inhibited by type II, but not type I RAFi MEK ERK RAF/MEK/ ERK PI3K/mTOR RAL Type II RAFi + Targeting multipl
Slide 21: Pimasertib MEK1/2 Inhibitor
Pimasertib MEK1/2 Inhibitor
Slide 22: Pimasertib: Allosteric MEK1/2 Inhibitor with Demonstrated Activity in MAPK-driven Solid Tumors
Pimasertib: Allosteric MEK1/2 Inhibitor with Demonstrated Activity in MAPK-driven Solid Tumors Sources: Pimasertib Investigator Brochure, v12, 2019; de Gooijer et al., Int J Cancer, 2018; Shaw et al., AACR LB-456, 2012; Lebbe et al., Cancers, 2020. Pimasertib is an orally-bioavailable, selective, no
Slide 23: Vertical MAPK Pathway Inhibition with DAY101 and Pimasertib Unlocks Potential Synergy
Vertical MAPK Pathway Inhibition with DAY101 (tovorafenib) and Pimasertib Unlocks Potential Synergy for Adult Solid Tumors The MAPK pathway normally has multiple feedback loops that negatively regulate upstream (RAS/RAF) activation to ensure optimal signaling Monotherapy MEK inhibition disables thes
Slide 24: DAY101 / Pimasertib Combination to be Evaluated in Solid Tumors (FIRELIGHT-1)
DAY101 (tovorafenib) / Pimasertib Combination to be Evaluated in Solid Tumors (FIRELIGHT-1) Abbreviations: BOIN, Bayesian Optimal Interval Design; BRAF, B-Raf proto-oncogene, serine/threonine kinase; MAPK, mitogen-activated protein kinase; NRAS, neuroblastoma rat sarcoma viral oncogene. 1Umbrella ma
Slide 25: Summary
Summary
Slide 26: Financial Summary: DAWN
Financial Summary: DAWN Cash and cash equivalents as of December 31, 2021: $284.3 million (no debt) IPO in May 2021: $184 million in gross proceeds, includes full exercise of underwriter’s option 62.0 million shares of common stock outstanding $ Millions Three Months Ended 12/31/21 Twelve Months End
Slide 27: Re-envisioning and Redefining Drug Development for People of All Ages – Starting at Day One
Re-envisioning and Redefining Drug Development for People of All Ages – Starting at Day One DAY101 (tovorafenib) Oral, CNS-penetrant, pan-RAF PIMASERTIB Oral, allosteric MEK inhibitor SPECIALIZED TEAM pLGG: most common brain tumor in children, with no approved therapies Rapid and durable responses d
Slide 28: Thank you
NY Day One = BIOPHARMACEUTICALS Thank you
Day One Biopharmaceuticals — Investor Presentation (March 2022) on 6ix